TargetBeta
DLL3
delta like canonical Notch ligand 3 · also SCDO1 · Canonical Notch ligands
16 programs in company-led studies act on DLL3, from 14 companies: 6 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 1312 running | CD3E | NCIt |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 1111 running | CD3E | NCIt |
| obrixtamig | Boehringer Ingelheim | phase 3 | 1111 running | CD3E | the company's pipeline |
| Zocilurtatug Pelitecanrule | Zai Lab | phase 3 | 66 running | – | NCIt |
| Anti-DLL3 Antibody-drug Conjugate BL-M14D1 | Sichuan Biokin Pharmaceutical | phase 3 | 44 running | – | the company's pipeline |
| gocatamig | Merck | phase 3 | 44 running | CD3E | a judged reading |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | IDEAYA Biosciences | phase 2 | 22 running | – | the company's pipeline |
| Autologous Anti-DLL3 CAR-T Cells DJI136 | Novartis | phase 2 | 22 running | – | the company's pipeline |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 11 running | CD3E | the company's pipeline |
| Anti-DLL3 Antibody-drug Conjugate FZ-AD005rule | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | phase 1 | 22 running | – | NCIt |
| clesitamig | Hoffmann-La Roche | phase 1 | 21 running | CD3E, TNFRSF9 | a judged reading |
| Actinium Ac 225-ABD147rule | Abdera Therapeutics | phase 1 | 11 running | – | NCIt |
| Actinium Ac 225-ETN029 | Novartis | phase 1 | 11 running | – | the company's pipeline |
| Autologous Anti-DLL3 CAR/CARD11-PIK3R3 Fusion Transgene-expressing T-cells ML261rule | Moonlight Bio | phase 1 | 11 running | CARD11, PIK3R3 | NCIt |
| HLX3901 | Fosun Pharma | phase 1 | 11 running | CD28, CD3E | the company's pipeline |
| Indium In 111-ETN029 | Novartis | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Small Cell Lung Carcinoma, 14 programs
- Carcinoma, Neuroendocrine, 3 programs
- Prostatic Neoplasms, 2 programs
- Glioblastoma, 1 program
- Glioma, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Alveltamig · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT06592638
- Dec 2026Anti-DLL3 Antibody-drug Conjugate IDE849 · IDEAYA Biosciences · phase 2 · NCT06443489
- Dec 2026SHR-7787 · Jiangsu HengRui Medicine · phase 2 · NCT06605222
- Dec 15, 2026obrixtamig · Boehringer Ingelheim · phase 3 · NCT05963867
- Apr 24, 2027tarlatamab · Amgen · phase 3 · NCT06598306
- May 30, 2027Zocilurtatug Pelitecan · Zai Lab · phase 3 · NCT06179069
- Jun 2027Anti-DLL3 Antibody-drug Conjugate BL-M14D1 · Sichuan Biokin Pharmaceutical · phase 3 · NCT06505824
- Dec 2027Autologous Anti-DLL3 CAR-T Cells DJI136 · Novartis · phase 2 · NCT05680922
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.